AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Understanding Patient Experiences with GLP-1 RA Among Adults with Obesity and Diabetes: A Large-Language Model Based Analysis of Electronic Health Record Discussions
By Babu C, Kim J, Eltahir A et al.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have transformed cardiometabolic health, by promoting weight loss, glycemic control and reducing cardiovascular risk. Despite these benefits, close to 50% of patients discontinue GLP-1 RA within the first year, limiting their overall effectiveness. There is a paucity of literature describing the patient experience with GLP-1 RA, which may provide insight toward improving overall adherence. Research Question/Hypothesis: We sought to characterize patient perspectives on GLP-1 RA therapy among adults with obesity and type 2 diabetes, including adverse effects, barriers to access and adherence, and reasons for inadequate dose titration or discontinuation within 180 days of treatment initiation. Methods: Using ICD-10 codes for obesity and type 2 diabetes, we identified patients prescribed GLP-1 RAs between 2020 and 2025. Large language model (LLM) tools were used to analyze patient-clinician messages referencing GLP-1 medications by generic or brand name. Topic modeling characterized reported adverse effects and clinical management strategies, including during dose escalation. Emergency department visits and hospitalizations within 180 days of initiation were evaluated to identify factors associated with discontinuation. Results: Among 4473 patients with obesity and diabetes, 2236 (50.0%) were prescribed a GLP-1 RA, and 1340 (60.0%) sent at least one message after prescription. Overall, 58.4% of patients directly referenced a GLP-1 RA in communications, yielding 3595 messages. These included symptom-related concerns (n=1129) and non-symptom-related concerns (n=2330). Gastrointestinal symptoms were most common (49.5%). Nausea/vomiting were strongly associated with hospitalization within 180 days (OR 4.99, 95% CI 1.45-17.1), as were fatigue/low energy (OR 3.52, 95% CI 1.22-10.2) and neurologic symptoms including headache and dizziness (OR 5.95, 95% CI 1.03-34.6). Patients experiencing symptoms that resulted in acute care utilization were more likely to discontinue therapy at both 90 days (OR 4.43, 95% CI 1.37-14.3) and 180 days (OR 2.64, 95% CI 1.01-6.92). Conclusions: In this LLM-based analysis of patient-clinician communications, patient-reported adverse effects were associated with increased acute care utilization and hospitalization. Patients requiring acute care were also more likely to discontinue GLP-1 RA therapy. Common reasons for acute care evaluation included gastrointestinal symptoms, fatigue, low energy, and mood-related concerns. Better understanding the patient experience may improve adherence, facilitate adverse-effect management, and reduce avoidable healthcare utilization.